Clinical Trial Update: A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing ocrelizumab to interferon beta-1a in relapsing multiple sclerosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Interferon-Beta-1a (Rebif) (Interferon beta-1a)
• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Relapsing Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2017-07-18